Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?
Nearly two months after getting the boot from the NIH’s ACTIV-3 study over a failed futility analysis, Novartis and Molecular Partners are back with mid-stage results they say prove their Covid-19 antiviral works better in patients who aren’t hospitalized — and CEO Vas Narasimhan likes what he sees.
The pharma giant is putting down more than $162 million to in-license ensovibep from Molecular Partners after the candidate met its primary endpoint of viral load reduction over eight days in the first part of a Phase II/III study, the partners announced on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
